PL3288940T3 - Azabenzimidazole i ich zastosowanie jako modulatory receptora ampa - Google Patents
Azabenzimidazole i ich zastosowanie jako modulatory receptora ampaInfo
- Publication number
- PL3288940T3 PL3288940T3 PL16723204T PL16723204T PL3288940T3 PL 3288940 T3 PL3288940 T3 PL 3288940T3 PL 16723204 T PL16723204 T PL 16723204T PL 16723204 T PL16723204 T PL 16723204T PL 3288940 T3 PL3288940 T3 PL 3288940T3
- Authority
- PL
- Poland
- Prior art keywords
- azabenzimidazoles
- receptor modulators
- ampa receptor
- ampa
- modulators
- Prior art date
Links
- 102000003678 AMPA Receptors Human genes 0.000 title 1
- 108090000078 AMPA Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154313P | 2015-04-29 | 2015-04-29 | |
| PCT/US2016/029801 WO2016176460A1 (en) | 2015-04-29 | 2016-04-28 | Azabenzimidazoles and their use as ampa receptor modulators |
| EP16723204.0A EP3288940B9 (en) | 2015-04-29 | 2016-04-28 | Azabenzimidazoles and their use as ampa receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3288940T3 true PL3288940T3 (pl) | 2021-07-12 |
Family
ID=56008859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16723204T PL3288940T3 (pl) | 2015-04-29 | 2016-04-28 | Azabenzimidazole i ich zastosowanie jako modulatory receptora ampa |
Country Status (39)
| Country | Link |
|---|---|
| US (5) | US11312712B2 (pl) |
| EP (3) | EP3288940B9 (pl) |
| JP (2) | JP6800886B2 (pl) |
| KR (2) | KR20170140382A (pl) |
| CN (1) | CN107835814B (pl) |
| AR (1) | AR104447A1 (pl) |
| AU (2) | AU2016255434C1 (pl) |
| BR (2) | BR112017023147B1 (pl) |
| CA (1) | CA2983826A1 (pl) |
| CO (1) | CO2017011017A2 (pl) |
| CR (1) | CR20170484A (pl) |
| CY (1) | CY1124059T1 (pl) |
| DK (1) | DK3288940T5 (pl) |
| EA (1) | EA033281B1 (pl) |
| EC (1) | ECSP17074645A (pl) |
| ES (1) | ES2865330T3 (pl) |
| GT (1) | GT201700231A (pl) |
| HR (1) | HRP20210403T1 (pl) |
| HU (1) | HUE053943T2 (pl) |
| IL (1) | IL254848B (pl) |
| JO (1) | JO3654B1 (pl) |
| LT (1) | LT3288940T (pl) |
| MA (1) | MA41988B1 (pl) |
| MD (1) | MD3288940T2 (pl) |
| MX (1) | MX376113B (pl) |
| MY (1) | MY194104A (pl) |
| NI (1) | NI201700129A (pl) |
| PH (1) | PH12017501816B1 (pl) |
| PL (1) | PL3288940T3 (pl) |
| PT (1) | PT3288940T (pl) |
| RS (1) | RS61688B1 (pl) |
| SG (1) | SG11201708190UA (pl) |
| SI (1) | SI3288940T1 (pl) |
| SM (1) | SMT202100222T1 (pl) |
| TW (1) | TWI706952B (pl) |
| UA (1) | UA120304C2 (pl) |
| UY (1) | UY36654A (pl) |
| WO (1) | WO2016176460A1 (pl) |
| ZA (1) | ZA201708065B (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2865330T3 (es) | 2015-04-29 | 2021-10-15 | Janssen Pharmaceutica Nv | Azabenzimidazoles y su uso como moduladores del receptor AMPA |
| JP6800885B2 (ja) * | 2015-04-29 | 2020-12-16 | ヤンセン ファーマシューティカ エヌ．ベー． | イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用 |
| SG11202000555UA (en) | 2017-06-21 | 2020-02-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| CN107383004B (zh) * | 2017-07-05 | 2020-04-17 | 浙江大学 | 2-氨基咪唑并吡啶类衍生物及制备和应用 |
| CN111315735B (zh) * | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
| US11447488B2 (en) | 2017-10-06 | 2022-09-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| CN120365272A (zh) | 2018-10-05 | 2025-07-25 | 安娜普尔纳生物股份有限公司 | 用于治疗与apj受体活性有关的疾病的化合物和组合物 |
| WO2020087170A1 (en) * | 2018-10-30 | 2020-05-07 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |
| AU2020222881B2 (en) | 2019-02-13 | 2025-07-10 | Ptc Therapeutics, Inc. | Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia |
| US12398140B2 (en) | 2019-02-13 | 2025-08-26 | Ptc Therapeutics, Inc. | Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia |
| JP7617076B2 (ja) * | 2019-07-22 | 2025-01-17 | リペア セラピューティクス インコーポレイテッド | Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 |
| EP4263523A2 (en) * | 2020-12-16 | 2023-10-25 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN114591338B (zh) * | 2022-03-31 | 2023-05-09 | 苏州欧康维视生物科技有限公司 | 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途 |
| CN115304599A (zh) * | 2022-09-20 | 2022-11-08 | 浙大宁波理工学院 | 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法 |
| CN117402148A (zh) * | 2023-07-26 | 2024-01-16 | 青岛大学 | 一种氮-氮苯并咪唑轴手性化合物及其制备方法和应用 |
| WO2025155830A1 (en) | 2024-01-17 | 2025-07-24 | Rapport Therapeutics, Inc. | Crystalline forms of 3-(7-chloro-1h-indazol-5-yl)-2,5-bis(trifluoromethyl)-3h-imidazo[4,5-b]pyridine and their use in the treatment of epilepsy |
| KR20250113344A (ko) * | 2024-01-17 | 2025-07-25 | 주식회사 엘지화학 | CBP/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물 |
| WO2025217330A1 (en) * | 2024-04-10 | 2025-10-16 | Terremoto Biosciences, Inc. | Cysteine covalent modifiers of akt1 and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55167282A (en) | 1979-06-12 | 1980-12-26 | Fujisawa Pharmaceut Co Ltd | Piperazine derivative or its salt and its preparation |
| CN1051313A (zh) | 1990-11-07 | 1991-05-15 | 鞍山市振东工业尼龙厂 | 尼龙球磨罐及其热装工艺 |
| GB9210400D0 (en) * | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
| TW251284B (pl) * | 1992-11-02 | 1995-07-11 | Pfizer | |
| AU685881B2 (en) | 1994-02-10 | 1998-01-29 | Pfizer Inc. | 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists |
| US5565483A (en) | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
| UA54403C2 (uk) | 1996-10-01 | 2003-03-17 | Н'Юросерч А/С | Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму |
| US6613777B1 (en) | 1998-03-06 | 2003-09-02 | Chen Chen | CRF antagonistic pyrazolo[4,3-b]pyridines |
| DE19812331A1 (de) | 1998-03-20 | 1999-09-23 | Merck Patent Gmbh | Piperidinderivate |
| WO2000001376A2 (en) * | 1998-07-02 | 2000-01-13 | Eisai Co., Ltd | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| EP1139754A4 (en) | 1998-12-31 | 2002-12-18 | Sugen Inc | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATION OF PROTEIN KINASE ACTIVITY AND IN CANCER CHEMOTHERAPY |
| GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| WO2002014294A2 (en) | 2000-08-11 | 2002-02-21 | Eli Lilly And Company | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function |
| US6548576B1 (en) | 2001-11-07 | 2003-04-15 | Bourns, Inc. | Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| PL1786812T3 (pl) * | 2004-09-03 | 2012-04-30 | Merck Serono Sa | Pirydynometylenoazolidynony i ich zastosowanie jako inhibitorów fosfoinozytydów |
| WO2007036715A2 (en) | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
| WO2007135529A2 (en) | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Azabenzimidazolyl compounds as mglur2 potentiators |
| EP2086643B1 (en) | 2006-11-03 | 2011-03-23 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| WO2008113795A1 (en) | 2007-03-20 | 2008-09-25 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| GB0711089D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| WO2009067607A2 (en) | 2007-11-20 | 2009-05-28 | Memory Pharmaceuticals Corporation | Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders |
| AU2008333865A1 (en) | 2007-12-06 | 2009-06-11 | Schering Corporation | Gamma secretase modulators |
| TW201012803A (en) | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| WO2010005528A2 (en) | 2008-06-30 | 2010-01-14 | Ironwood Pharmaceuticals Incorporated | Pyrrolopyridine carboxylic acid derivatives |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0822425D0 (en) | 2008-12-09 | 2009-01-14 | Glaxo Group Ltd | Compounds |
| GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| WO2011056985A2 (en) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
| CN102892288B (zh) | 2010-02-11 | 2016-02-24 | 范德比尔特大学 | 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法 |
| EP2579717A4 (en) * | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| AU2011270994B2 (en) | 2010-06-24 | 2015-12-10 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors |
| EA022078B1 (ru) | 2010-08-10 | 2015-10-30 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение и его применение |
| US8993779B2 (en) | 2010-08-12 | 2015-03-31 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of MGLUR2 |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| WO2013130501A1 (en) | 2012-03-01 | 2013-09-06 | The Board Of Regents Of The University Of Texas System | Bivalent ampa receptor positive allosteric modulators |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| JO3225B1 (ar) | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
| EA201591360A1 (ru) * | 2013-02-19 | 2016-03-31 | Пфайзер Инк. | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств |
| TW201609719A (zh) | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物 |
| EP3626720A1 (en) | 2015-04-03 | 2020-03-25 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| ES2865330T3 (es) | 2015-04-29 | 2021-10-15 | Janssen Pharmaceutica Nv | Azabenzimidazoles y su uso como moduladores del receptor AMPA |
| WO2018080916A1 (en) | 2016-10-26 | 2018-05-03 | Janssen Pharmaceutica Nv | Fused azaheterocyclic compounds and their use as ampa receptor modulators |
| WO2018080918A1 (en) | 2016-10-26 | 2018-05-03 | Janssen Pharmaceutica Nv | 3-aryl-2h-pyrazolo[4,3-b]pyridine compounds and their use as ampa receptor modulators |
| JP6953527B2 (ja) | 2016-10-26 | 2021-10-27 | ヤンセン ファーマシューティカ エヌ．ベー． | 縮合二環ピリジン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用 |
| BR112020020708A8 (pt) | 2018-04-09 | 2022-10-18 | Raqualia Pharma Inc | Derivados da ureia cíclica fundidã como antagonista crhr2 |
| JP7532386B2 (ja) | 2019-02-01 | 2024-08-13 | ハンミ ファーマシューティカルズ カンパニー リミテッド | イミダゾピリジン誘導体化合物及びその用途 |
-
2016
- 2016-04-28 ES ES16723204T patent/ES2865330T3/es active Active
- 2016-04-28 MA MA41988A patent/MA41988B1/fr unknown
- 2016-04-28 EA EA201792374A patent/EA033281B1/ru unknown
- 2016-04-28 EP EP16723204.0A patent/EP3288940B9/en active Active
- 2016-04-28 BR BR112017023147-6A patent/BR112017023147B1/pt active IP Right Grant
- 2016-04-28 LT LTEP16723204.0T patent/LT3288940T/lt unknown
- 2016-04-28 SM SM20210222T patent/SMT202100222T1/it unknown
- 2016-04-28 TW TW105113298A patent/TWI706952B/zh active
- 2016-04-28 UA UAA201711635A patent/UA120304C2/uk unknown
- 2016-04-28 KR KR1020177034350A patent/KR20170140382A/ko not_active Abandoned
- 2016-04-28 EP EP21157913.1A patent/EP3901153A1/en active Pending
- 2016-04-28 MD MDE20180234T patent/MD3288940T2/ro unknown
- 2016-04-28 BR BR122023023802-8A patent/BR122023023802A2/pt not_active Application Discontinuation
- 2016-04-28 SG SG11201708190UA patent/SG11201708190UA/en unknown
- 2016-04-28 DK DK16723204.0T patent/DK3288940T5/da active
- 2016-04-28 UY UY0001036654A patent/UY36654A/es active IP Right Grant
- 2016-04-28 AR ARP160101217A patent/AR104447A1/es active IP Right Grant
- 2016-04-28 KR KR1020247003619A patent/KR102782808B1/ko active Active
- 2016-04-28 JP JP2017556634A patent/JP6800886B2/ja active Active
- 2016-04-28 CN CN201680038830.0A patent/CN107835814B/zh active Active
- 2016-04-28 MX MX2017013886A patent/MX376113B/es active IP Right Grant
- 2016-04-28 SI SI201631171T patent/SI3288940T1/sl unknown
- 2016-04-28 EP EP22200371.7A patent/EP4144736A1/en active Pending
- 2016-04-28 HR HRP20210403TT patent/HRP20210403T1/hr unknown
- 2016-04-28 PH PH1/2017/501816A patent/PH12017501816B1/en unknown
- 2016-04-28 CA CA2983826A patent/CA2983826A1/en active Pending
- 2016-04-28 US US15/569,299 patent/US11312712B2/en active Active
- 2016-04-28 CR CR20170484A patent/CR20170484A/es unknown
- 2016-04-28 WO PCT/US2016/029801 patent/WO2016176460A1/en not_active Ceased
- 2016-04-28 AU AU2016255434A patent/AU2016255434C1/en active Active
- 2016-04-28 HU HUE16723204A patent/HUE053943T2/hu unknown
- 2016-04-28 MY MYPI2017703998A patent/MY194104A/en unknown
- 2016-04-28 RS RS20210362A patent/RS61688B1/sr unknown
- 2016-04-28 PL PL16723204T patent/PL3288940T3/pl unknown
- 2016-04-28 JO JOP/2016/0085A patent/JO3654B1/ar active
- 2016-04-28 PT PT167232040T patent/PT3288940T/pt unknown
-
2017
- 2017-10-02 IL IL254848A patent/IL254848B/en active IP Right Grant
- 2017-10-27 NI NI201700129A patent/NI201700129A/es unknown
- 2017-10-27 GT GT201700231A patent/GT201700231A/es unknown
- 2017-10-27 CO CONC2017/0011017A patent/CO2017011017A2/es unknown
- 2017-11-10 EC ECIEPI201774645A patent/ECSP17074645A/es unknown
- 2017-11-28 ZA ZA2017/08065A patent/ZA201708065B/en unknown
-
2020
- 2020-07-30 AU AU2020210231A patent/AU2020210231B2/en active Active
- 2020-11-25 JP JP2020195323A patent/JP7026194B2/ja active Active
-
2021
- 2021-04-23 CY CY20211100354T patent/CY1124059T1/el unknown
- 2021-05-19 US US17/324,520 patent/US12304908B2/en active Active
-
2022
- 2022-10-17 US US17/967,483 patent/US12139485B2/en active Active
- 2022-10-17 US US17/967,508 patent/US12145934B2/en active Active
-
2025
- 2025-02-20 US US19/059,130 patent/US20250230157A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201708065B (en) | Azabenzimidazoles and their use as ampa receptor modulators | |
| IL291598A (en) | History of benzodiazepine cytotoxicity | |
| ZA201800827B (en) | Substituted 4-azaindoles and their use as glun2b receptor modulators | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| IL249896B (en) | New modulators for the glp-1 receptor and their use as drugs | |
| EP3215893C0 (en) | ELECTRO-OPTICAL TILE | |
| IL247599B (en) | Formulation that suppresses the immune system | |
| IL254921B (en) | Pyridopyrimidinones and their uses as nmda receptor modulators | |
| GB201502412D0 (en) | Therapeutic use | |
| GB201414116D0 (en) | Benzodiazepine derivatives | |
| IL255420A0 (en) | Selective modulators of gpr55 receptor activity: chromopyrazole derivatives | |
| GB201409653D0 (en) | Pyrrolobenzodiazepine therapeutic agents | |
| GB201506786D0 (en) | Therapeutic use | |
| AU2014324V (en) | MALOF002 Acmena smithii | |
| GB201410387D0 (en) | Compounds and their therapeutic use | |
| GB201403496D0 (en) | Compounds and their therapeutic use | |
| GB201400215D0 (en) | Modulators |